BioTech Industry Overview |
| | | | |
Global | Amount | Units | Year | Source |
Public & Private Biotech Companies | 4,275 | Companies | 2006 | E&Y |
Public Biotech Companies | 710 | Companies | 2006 | E&Y |
Revenues | 73.5 | Bil. US$ | 2006 | E&Y |
Increase from 2005 | 14 | % | 2006 | E&Y |
R&D Expenses | 27.8 | Bil. US$ | 2006 | E&Y |
Net Income | -5.4 | Bil. US$ | 2006 | E&Y |
Number of Employees | 190.5 | Thousand | 2006 | E&Y |
Total Pharmaceutical Sales, Worldwide | 643.0 | Bil. US$ | 2006 | IMS |
Total R&D Expenses, PhRMA Member Companies | 43.0 | Bil. US$ | 2006 | PhRMA |
Total R&D Expenses, All Pharmaceutical Companies | 55.2 | Bil. US$ | 2006 | Burrill |
U.S. |
Public & Private Biotech Companies | 1,452 | Companies | 2006 | E&Y |
Public Biotech Companies | 336 | Companies | 2006 | E&Y |
Revenues | 55.5 | Bil. US$ | 2006 | E&Y |
R&D Expenses | 22.9 | Bil. US$ | 2006 | E&Y |
Net Income | -3.5 | Bil. US$ | 2006 | E&Y |
Number of Employees | 130.6 | Thousand | 2006 | E&Y |
Total Biotech Company Financing | 20.3 | Bil. US$ | 2006 | E&Y |
Pharmaceutical Sales1, Domestic | 174.7 | Bil. US$ | 2006 | PhRMA |
% Generic (by volume) | 58 | % | 2007 | PhRMA |
Pharmaceutical Sales1, Foreign2 | 71.1 | Bil. US$ | 2006 | PhRMA |
Branded Biotech Drug Sales, U.S. | 40.3 | Bil. US$ | 2006 | IMS |
Prescriptions Filled, U.S., 12 month period ending Sept. | 3.6 | Bil. | 2005 | PhRMA |
Total Pharmaceutical Company Spending on R&D1 | 43.0 | Bil. US$ | 2006 | PhRMA |
as a Percentage of All Sales1 | 16.9 | % | 2005 | PhRMA |
| Share of R&D Spending by Function: |
Prehuman/Preclinical | 25.7 | % | 2005 | PhRMA |
Phase I | 5.8 | % | 2005 | PhRMA |
Phase II | 11.7 | % | 2005 | PhRMA |
Phase III | 25.5 | % | 2005 | PhRMA |
Approval | 6.9 | % | 2005 | PhRMA |
Phase IV | 13.3 | % | 2005 | PhRMA |
Uncategorized | 11.0 | % | 2005 | PhRMA |
Average Time Required for Clinical Trials, from Discovery through Phase IV | 16 | Years | 2007 | PhRMA |
Average Cost of Developing a Biologic Drug | 1.2 | Bil. US$ | 2005 | Tufts |
Number of FDA Approvals for New Drugs (NDAs) | 101 | Approvals | 2006 | FDA |
Number of Approvals for New Molecular Entities (NMEs) | 22 | Approvals | 2006 | FDA |
Patents Granted for "Multicellular Living Organisms and Unmodified Parts Thereof" Since 1970 | 5,644 | Patents | 2005 | USPTO |
Total Requested Proposed for Biological Science Research, U.S. National Science Foundation | 633.0 | Mil. US$ | 2008 | NSF |
Average Annual Salary for Biochemists & Biophysicists | 80,900 | US$ | May-06 | BLS |
| 1 PhRMA Member Companies. 2 Not including foreign divisions of foreign companies. |
| E&Y = Ernst & Young; PhRMA = Pharmaceutical Research and Manufacturers Association; Burrill = Burrill & Company; IMS = IMS Health; Tufts = Tufts Center for the Study of Drug Development; FDA = U.S. Food & Drug Administration; USPTO = U.S. Patent & Trademark Office; NSF = U.S. National Science Foundation; BLS = U.S. Bureau of Labor Statistics |
Source: Plunkett Research, Ltd.
Plunkett's Biotech & Genetics Industry Almanac 2008
Copyright© 2007, All Rights Reserved |